ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 105 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,334 | -74.7% | 565 | -64.4% | 0.00% | – |
| Q2 2023 | $44,713 | +212819.0% | 1,585 | +27.3% | 0.00% | – |
| Q1 2023 | $21 | -12.5% | 1,245 | +2.5% | 0.00% | – |
| Q4 2022 | $24 | -99.9% | 1,215 | -1.9% | 0.00% | – |
| Q3 2022 | $31,000 | -8.8% | 1,238 | +3.2% | 0.00% | – |
| Q2 2022 | $34,000 | -37.0% | 1,200 | +1.7% | 0.00% | – |
| Q1 2022 | $54,000 | -30.8% | 1,180 | -13.2% | 0.00% | -100.0% |
| Q4 2021 | $78,000 | -30.4% | 1,360 | -19.0% | 0.00% | 0.0% |
| Q3 2021 | $112,000 | +25.8% | 1,680 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $89,000 | – | 1,680 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |